期刊文献+

CT引导^(125)I近距离挽救治疗胃肠胰神经内分泌瘤的临床应用分析

CT guidesalvage therapy of gastrointestinal pancreatic neuroendocrine tumor's recurrence and metastasis
下载PDF
导出
摘要 目的探讨CT引导胃肠胰神经内分泌瘤(GEP-NET)复发和转移的^(125)I近距离挽救治疗。方法 12例胃肠胰神经内分泌瘤复发和转移患者,采用^(125)I放射性粒子进行挽救治疗。所有患者经病理确诊并经过通过系统的手术治疗或者化疗,4例经过生物治疗后复发。其中男4例,女8例,年龄42~79岁,中位年龄56岁。处方剂量(PD)范围为90~140Gy,计划靶体积(PTV)为肿瘤靶体积(GTV)外各个方向上均匀外扩1cm。结果 12例患者均完成2~4次不等的放射性粒子治疗,3、6、9、12、18月局部控制率分别为100%、100%、84.62%、61.54%、38.46.5%,放射性粒子治疗并发症:少量出血3例,皮肤色素沉着1例。结论 CT引导^(125)I近距离治疗作为GEP-NET复发或者转移性的挽救性治疗安全有效。 Objective To discuss how to use CT to guide treatment of iodine-125 for the recurrence and metastatic of the gas-trointestinal pancreatic neuroendocrine tumor ( gep-net ) . Methods 12 patients with gastrointestinal pancreatic neuroendocrine tumor recurrence and metastasis are treated with the iodine-125 radioactive particles. All patients are pathologicaldiagnosed and treated by surgery or chemotherapy systematically, in which 4 cases reoccur after biological treatment, including 4 males and 8 fe-males;aged from 42 to 79 years, median age 56 years old. Prescribed dose ( PD) range is 90~140 Gy, planning target volume ( PTV) is the tumor target volume ( GTV) uniformly enlarged 1 cmin in all directions. Results 12 cases all finished 2~ 4 time-streatment of radioactive particles, the local control rates of 3, 6, 9, 12 and 18 months were 100%, 100%, 84. 62%, 61. 54%, 38. 46. 5%. The complications of the radioactive particles treatment include a small amount of bleeding in 3 cases, skin pigmenta-tion in 1 case. Conclusion CT guide iodine-125particles to closely treat the recurrence and metastatic of GEP-NET is safe and effective.
出处 《医学影像学杂志》 2017年第9期1757-1759,1763,共4页 Journal of Medical Imaging
关键词 胃肠胰腺肿瘤 神经内分泌瘤 125I放射性粒子 治疗 Gastrointestinal pancreatic tumor Neuroendocrine tumor Iodine-125 radioactive particles Treatment
  • 相关文献

参考文献2

二级参考文献49

  • 1杨宏,周雷,王文跃.胃肠胰神经内分泌肿瘤治疗新进展[J].中华临床医师杂志(电子版),2011,5(16):4808-4812. 被引量:2
  • 2Yao Jc,Hassan M,Phan A. One hundred years after"carcinoid":epidemiology of and prognostic factors forneuroendocrine tumors in 35,825 cases in the United States[J].J Clin Ontol,2008.3063-3072.
  • 3Modlin IM,Oberg K,Chung DC. Gastroenteropancreatic neufoendocrine tumours[J].LANCET ONCOLOGY,2008.61-72.
  • 4Modlin IM,Lye KD,Kidd M. A 5-decade analysis of 13,715carcinoid tumors[J].CANCER,2003.934-959.
  • 5Luke C,Price T,Townsend A. Epidemiology of neuroendoerine cancers in an Australian population[J].Cancer Causes & Control,2010.931-938.
  • 6Oberg K. Neuroendocrine tumors (NETs):historical overview and epidemiology[J].TUMORI,2010.797-801.
  • 7Hauso O,Gastafsson BI,Kidd M. Neuroendocriae tumor epidemiology:contrasting Norway and North America[J].CANCER,2008.2655-2664.
  • 8Kunz PL,Fisher GA. Advances in the treatment of gastroenteropancreatic neuroendocrine tumors[J].Clin Experiment Gastroenteml,2010.79-86.
  • 9Ito T,Sasano H,Tanaka M. Epidemiological study of gastroenteropanereatic neuroendocrine tumors in Japan[J].Journal of Gastroenterology,2010.234-243.
  • 10Ramage JK,Davies AH,Ardill J. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours[J].GUT,2005,(Suppl 4):iv1-iv16.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部